Eventide Healthcare Life Fund Investor Sentiment

ETNHX Fund  USD 34.23  0.43  1.27%   
Slightly above 51% of Eventide Healthcare's investors are presently thinking to get in. The analysis of overall sentiment of trading Eventide Healthcare Life mutual fund suggests that some investors are interested at this time. Eventide Healthcare's investing sentiment can be driven by a variety of factors including economic data, Eventide Healthcare's earnings reports, geopolitical events, and overall market trends.
  
over a year ago at www.macroaxis.com         
Payment of 635 shares by Stephen Webster of Spark Therapeutics subject to Rule 16b-3
Macroaxis News
over a year ago at news.google.com         
Rain Oncology Multiple Data Catalysts In 2023 For This Precision ... - Seeking Alpha
Google News at Macroaxis
over three months ago at seekingalpha.com         
Tectonic, AVROBIO complete merger, announce 130.7M private placement
seekingalpha News
over three months ago at news.google.com         
Gabelli Funds LLC Invests 467000 in AVROBIO, Inc. - Defense World
Google News at Macroaxis
over three months ago at news.google.com         
AVROBIO, Inc. Short Interest Up 11.3 percent in May - MarketBeat
Google News at Macroaxis
over six months ago at investing.com         
Avrobio executive buys shares worth over 970k
Investing News at Macroaxis
over six months ago at investorplace.com         
AVRO Stock Earnings Avrobio Beats EPS for Q1 2024
sbwire news
over six months ago at news.google.com         
AVROBIO Options Chain Prices 2024 - MarketBeat
Google News at Macroaxis
over six months ago at news.google.com         
AVROBIO Posts Quarterly Earnings Results - MarketBeat
Google News at Macroaxis
over six months ago at thelincolnianonline.com         
AVROBIO, Inc. Sees Significant Drop in Short Interest
news
over six months ago at benzinga.com         
SHAREHOLDER UPDATE Halper Sadeh LLC Investigates AXNX, KAMN, JNPR, AVRO
benzinga news
over six months ago at news.google.com         
AVROBIO INVESTOR ALERT by the Former Attorney General of Louisiana Kahn Swick Foti, LLC Investigates...
Google News at Macroaxis
2 days ago at news.google.com         
Supernus Pharmaceuticals, Inc. Shares Acquired by Pacer Advisors Inc. - MarketBeat
Google News at Macroaxis
over a week ago at gurufocus.com         
ARMISTICE CAPITAL, LLC Acquires Significant Stake in Rockwell Medical Inc
Gurufocus Stories at Macroaxis
over a week ago at gurufocus.com         
ARMISTICE CAPITAL, LLC Acquires New Stake in Protagenic Therapeutics Inc
Gurufocus Stories at Macroaxis
over a week ago at gurufocus.com         
Supernus Pharmaceuticals Inc Shares Gap Down to 36.57 on Nov 14
Gurufocus Stories at Macroaxis
over a week ago at news.google.com         
Supernus Pharmaceuticals Recently Launched Qelbree Is Powering Growth - Seeking Alpha
Google News at Macroaxis
over two weeks ago at investing.com         
Supernus Pharmaceuticals director sells shares worth 520,480
Investing News at Macroaxis
over two weeks ago at finance.yahoo.com         
Supernus Pharmaceuticals Third Quarter 2024 Earnings Beats Expectations
Yahoo News
over two weeks ago at finance.yahoo.com         
Supernus Reports Q3 Earnings What Key Metrics Have to Say
Yahoo News
over two weeks ago at finance.yahoo.com         
Supernus Pharmaceuticals Inc Q3 2024 Earnings Call Highlights Strong Revenue Growth and ...
Yahoo News
over two weeks ago at seekingalpha.com         
Supernus Pharmaceuticals GAAP EPS of 0.69, revenue of 175.69M beats by 18.39M
seekingalpha News
a minute ago at thelincolnianonline.com         
AbbVie Inc. Shares Sold by Janney Montgomery Scott LLC
news
2 days ago at cnbc.com         
Jim Cramer is bullish on cybersecurity stocks, saying two industry leaders are buys
cnbc News
3 days ago at thelincolnianonline.com         
Massachusetts Financial Services Co. MA Purchases 373,802 Shares of AbbVie Inc.
news
few days ago at finance.yahoo.com         
Is Trending Stock AbbVie Inc. a Buy Now?
Yahoo News
few days ago at thelincolnianonline.com         
OneAscent Financial Services LLC Lowers Holdings in AbbVie Inc.
news
few days ago at thelincolnianonline.com         
AbbVie Inc. Holdings Cut by Knuff Co LLC
news
few days ago at prnewswire.com         
AbbVie Receives European Commission Approval of ELAHERE for the Treatment of Platinum-Resistant Ovar...
prnewswire News
few days ago at seekingalpha.com         
AbbVie snaps eight straight sessions of losses
seekingalpha News
six days ago at thelincolnianonline.com         
Schear Investment Advisers LLC Invests 267,000 in AbbVie Inc.
news
over a week ago at insidermonkey.com         
Why AbbVies Drug Setback Creates A Prime Buy-The-Dip Moment
insidermonkey News
2 days ago at gurufocus.com         
Insider Sell Alert Karin Eastham Sells 14,731 Shares of Veracyte Inc
Gurufocus Stories at Macroaxis
few days ago at gurufocus.com         
Disposition of 10125 shares by Eastham Karin of Veracyte at 38.756 subject to Rule 16b-3
Gurufocus Stories at Macroaxis
over a week ago at investing.com         
Wolfe Research sets stock target on Veracyte, cites growth potential
Investing News at Macroaxis
over a week ago at investing.com         
Veracyte CFO Rebecca Chambers sells 585,663 in company stock
Investing News at Macroaxis
over a week ago at simplywall.st         
Veracyte, Inc. Is About To Turn The Corner
Simply Wall St News at Macroaxis
over a week ago at thelincolnianonline.com         
Veracyte, Inc. Given Average Rating of Moderate Buy by Analysts
news
over two weeks ago at thelincolnianonline.com         
Veracyte Posts Quarterly Earnings Results, Beats Expectations By 0.17 EPS
news
over two weeks ago at gurufocus.com         
Wellington Management Group LLPs Strategic Reduction in Veracyte Inc Holdings
Gurufocus Stories at Macroaxis
over two weeks ago at gurufocus.com         
Veracyte Inc Q3 2024 Earnings Call Highlights Record Revenue Growth and Strategic Outlook
Gurufocus Stories at Macroaxis
over two weeks ago at investing.com         
Earnings call Veracyte posts record Q3 revenue, raises 2024 guidance
Investing News at Macroaxis
3 days ago at investing.com         
Bluebird Bios SWOT analysis gene therapy firm faces cash crunch amid launch
Investing News at Macroaxis
over a week ago at simplywall.st         
bluebird bio, Inc.s Revenues Are Not Doing Enough For Some Investors
Simply Wall St News at Macroaxis
over a week ago at insidermonkey.com         
bluebird bio, Inc. Q3 2024 Earnings Call Transcript
insidermonkey News
over a week ago at benzinga.com         
JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options
benzinga news
over a week ago at investing.com         
Earnings call Bluebird bio sees patient growth, aims for 2025 breakeven
Investing News at Macroaxis
over a week ago at seekingalpha.com         
bluebird bio Q3 2024 Earnings Preview
seekingalpha News
over two weeks ago at zacks.com         
After Plunging -22.76 percent in 4 Weeks, Heres Why the Trend Might Reverse for Bluebird
zacks News
over two weeks ago at businesswire.com         
bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call
businesswire News
over two weeks ago at finance.yahoo.com         
bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cel...
Yahoo News
over two weeks ago at prnewswire.com         
BLUE SUEDE HOSPITALITY GROUP NAMES SHADE GROUP AS AGENCY OF RECORD
prnewswire News
over a year ago at finance.yahoo.com         
Antibody Drug Conjugates Global Market Report 2023
Yahoo News
2 days ago at news.google.com         
Pacer Advisors Inc. Trims Stock Holdings in Collegium Pharmaceutical, Inc. - MarketBeat
Google News at Macroaxis
six days ago at thelincolnianonline.com         
Collegium Pharmaceutical, Inc. Shares Purchased by Royce Associates LP
news
over a week ago at finance.yahoo.com         
Collegium Pharmaceuticals Performance Is Even Better Than Its Earnings Suggest
Yahoo News
over a week ago at zacks.com         
Is Collegium Pharmaceutical a Great Value Stock Right Now?
zacks News
over a week ago at gurufocus.com         
Insider Trading
Gurufocus Stories at Macroaxis
over two weeks ago at finance.yahoo.com         
Is the Options Market Predicting a Spike in Collegium Pharmaceutical Stock?
Yahoo News
over two weeks ago at investing.com         
Earnings call Collegium Pharmaceuticals reports strong Q3 growth
Investing News at Macroaxis
over two weeks ago at investing.com         
Collegium Pharmaceutical earnings beat by 0.04, revenue topped estimates
Investing News at Macroaxis
over two weeks ago at zacks.com         
Heres What Key Metrics Tell Us About Collegium Pharmaceutical Q3 Earnings
zacks News
over two weeks ago at finance.yahoo.com         
What To Expect From Collegium Pharmaceutical Inc Q3 2024 Earnings
Yahoo News
2 days ago at finance.yahoo.com         
BridgeBio heart drug approved by FDA, setting up battle with Pfizer
Yahoo News
few days ago at thelincolnianonline.com         
Swiss National Bank Has 103.25 Million Stock Holdings in Alnylam Pharmaceuticals, Inc.
news
few days ago at investing.com         
Alnylam stock holds price target and buy rating on promising drug data
Investing News at Macroaxis
few days ago at investing.com         
Alnylam shares hold Buy rating as TD Cowen notes sustained efficacy in interim Phase 1b results
Investing News at Macroaxis
six days ago at finance.yahoo.com         
Alnylam Announces Interim Phase 1 Data of Nucresiran Showing Rapid Knockdown of TTR that is Sustaine...
Yahoo News
over a week ago at bizjournals.com         
Mass. life science stocks plunge on prospect of RFK Jr. as HHS head
bizjournals News
over a week ago at finance.yahoo.com         
High Growth Tech Stocks Featuring ALSO Holding And 2 More
Yahoo News
over a week ago at simplywall.st         
Exploring 3 High Growth Tech Stocks in United States
Simply Wall St News at Macroaxis
over a week ago at investing.com         
Alnylam stock downgraded to underperform over long-term value concerns
Investing News at Macroaxis
over a week ago at investing.com         
Ionis Pharmaceuticals SWOT analysis RNA pioneers stock faces pivotal year
Investing News at Macroaxis
few days ago at news.google.com         
StockNews.com Upgrades Voyager Therapeutics to Buy - MarketBeat
Google News at Macroaxis
over a week ago at investing.com         
Oppenheimer reiterates Voyager stock target, sees positive outlook from TOGETHER study
Investing News at Macroaxis
over two weeks ago at finance.yahoo.com         
Arcus Biosciences, Inc. Reports Q3 Loss, Tops Revenue Estimates
Yahoo News
over three weeks ago at news.google.com         
Voyager Therapeutics Expected to Beat Earnings Estimates Can the Stock Move Higher - Yahoo Finance
Google News at Macroaxis
over a month ago at simplywall.st         
Improved Revenues Required Before Voyager Therapeutics, Inc. Stocks 27 percent Jump Looks Justified
Simply Wall St News at Macroaxis
over a month ago at zacks.com         
GSKs NDA for UTI Drug Gepotidacin Gets FDAs Priority Review
zacks News
over a month ago at finance.yahoo.com         
Investing in Voyager Therapeutics three years ago would have delivered you a 58 percent gain
Yahoo News
over a month ago at simplywall.st         
Strong week for Voyager Therapeutics shareholders doesnt alleviate pain of five-year loss
Simply Wall St News at Macroaxis
over a month ago at news.google.com         
Voyager Therapeutics stock hits 52-week low at 5.95 - Investing.com
Google News at Macroaxis
over two months ago at finance.yahoo.com         
Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabl...
Yahoo News
few days ago at investing.com         
Galapagos stock downgraded to Reduce on strategic concerns
Investing News at Macroaxis
over a week ago at gurufocus.com         
Stonepine Capital Management Reduces Stake in Evolus Inc
Gurufocus Stories at Macroaxis
over two weeks ago at thelincolnianonline.com         
Galapagos Sees Large Volume Increase Should You Buy?
news
over three weeks ago at thelincolnianonline.com         
Galapagos Shares Gap Down Time to Sell?
news
over a month ago at thelincolnianonline.com         
Galapagos NV Receives 31.00 Consensus Target Price from Analysts
news
over two months ago at benzinga.com         
Major Investor Says Galapagos Is Undervalued, Plans To Push On Companys Performance And Strategic Op...
benzinga news
over three months ago at seekingalpha.com         
Galapagos stock gains after FDA nod for trial
seekingalpha News
over three months ago at insidermonkey.com         
Galapagos NV Q2 2024 Earnings Call Transcript
insidermonkey News
over three months ago at seekingalpha.com         
Galapagos stock downgraded at Raymond James
seekingalpha News
over three months ago at seekingalpha.com         
Galapagos GAAP EPS of 1.51, revenue of 140.3M
seekingalpha News
over a year ago at thelincolnianonline.com         
Ionis Pharmaceuticals Given New 34.00 Price Target at SVB Leerink
news
over a year ago at hawaiinewsnow.com         
Purchase by Sumitomo Chemical Co Ltd of 51599200 shares of Myovant Sciences
news
a minute ago at finance.yahoo.com         
Genethon Pursues Different Strategies for Ensuring Patient Access to Gene Therapies for Rare Disease...
Yahoo News
2 days ago at thelincolnianonline.com         
Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3
news
few days ago at investing.com         
Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3
Investing News at Macroaxis
few days ago at finance.yahoo.com         
Disposition of 4558 shares by Rodino-klapac Louise of Sarepta Therapeutics at 102.89 subject to Rule...
Yahoo News
over a week ago at thelincolnianonline.com         
Simplify Asset Management Inc. Has 24.11 Million Stock Position in Sarepta Therapeutics, Inc.
news
over a week ago at gurufocus.com         
Janus Henderson Group PLCs Strategic Acquisition in Sarepta Therapeutics Inc
Gurufocus Stories at Macroaxis
over a week ago at investing.com         
Sarepta Therapeutics SWOT analysis stock poised for growth amid DMD market leadership
Investing News at Macroaxis
over a week ago at www.macroaxis.com         
Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3
Macroaxis News
over two weeks ago at thelincolnianonline.com         
Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3
news
over two weeks ago at insidermonkey.com         
Sarepta Therapeutics, Inc. Q3 2024 Earnings Call Transcript
insidermonkey News
over a year ago at news.google.com         
In SOTU speech, Biden says hell veto IRA repeal efforts - FiercePharma
Google News at Macroaxis
over six months ago at thelincolnianonline.com         
Mirati Therapeutics Now Covered by Analysts at StockNews.com
news
over six months ago at finance.yahoo.com         
Billionaire Joe Lewis Pleads Guilty in Insider Trading Case
Yahoo News
over six months ago at smh.com.au         
Billionaire pleads guilty in insider trading case with a link to an Australian giant
news
over six months ago at streetinsider.com         
Frances Sanofi to buy U.S. drugs project INBRX-101 for about 2.2 billion
Street Insider News
over six months ago at streetinsider.com         
Frances Sanofi to buy U.S. drugs project INBRX-101 for about 2.2 billion
Street Insider News
over six months ago at streetinsider.com         
Frances Sanofi to buy U.S. drugs project INBRX-101 for about 2.2 billion
Street Insider News
over six months ago at streetinsider.com         
Frances Sanofi to buy U.S. drugs project INBRX-101 for about 2.2 billion
Street Insider News
over six months ago at aol.com         
Frances Sanofi to buy U.S. drugs project INBRX-101 for about 2.2 billion
news
over six months ago at seekingalpha.com         
Mirati Therapeutics stock ticks higher amid Nasdaq delisting for sale to Bristol-Myers
seekingalpha News
over six months ago at thelincolnianonline.com         
Brokerages Set Mirati Therapeutics, Inc. PT at 60.00
news
over a year ago at news.google.com         
Eylea Race Continues To Heat Up With Formycon Unveiling Early ... - Generics Bulletin
Google News at Macroaxis
a minute ago at finance.yahoo.com         
Neurocrines Phase II schizophrenia trial fails to meet primary endpoint
Yahoo News
3 days ago at finance.yahoo.com         
Helpr Employer-Subsidized Family Care App with Patented My Choice Technology Expands Service to 150 ...
Yahoo News
few days ago at news.google.com         
Victory Capital Management Inc. Increases Holdings in Neurocrine Biosciences, Inc. - MarketBeat
Google News at Macroaxis
over a week ago at gurufocus.com         
BB Biotech AG Adjusts Stake in Ionis Pharmaceuticals
Gurufocus Stories at Macroaxis
over a week ago at finance.yahoo.com         
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
Yahoo News
over two weeks ago at finance.yahoo.com         
Neurocrine Biosciences Strong Earnings Are Of Good Quality
Yahoo News
over two weeks ago at thelincolnianonline.com         
Neurocrine Biosciences Receives Buy Rating from HC Wainwright
news
over two weeks ago at finance.yahoo.com         
Disposition of 2000 shares by Sherwin Stephen A of Neurocrine Biosciences subject to Rule 16b-3
Yahoo News
over three weeks ago at gurufocus.com         
Decoding Neurocrine Biosciences Inc A Strategic SWOT Insight
Gurufocus Stories at Macroaxis
over three weeks ago at investing.com         
Earnings call Neurocrine Biosciences reports strong Q3 growth, plans ahead
Investing News at Macroaxis
few days ago at finance.yahoo.com         
Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the...
Yahoo News
over a week ago at gurufocus.com         
Redmile Group, LLC Adjusts Stake in Krystal Biotech Inc
Gurufocus Stories at Macroaxis
over two weeks ago at simplywall.st         
Subdued Growth No Barrier To Nurix Therapeutics, Inc. With Shares Advancing 25
Simply Wall St News at Macroaxis
over two weeks ago at investing.com         
Disposition of 3290 shares by Christine Ring of Nurix Therapeutics at 25.0 subject to Rule 16b-3
Investing News at Macroaxis
over three weeks ago at investing.com         
Nurix therapeutics CFO Hans van Houte sells 86,083 in stock
Investing News at Macroaxis
over three weeks ago at investing.com         
Nurix therapeutics CFO Hans van Houte sells 57,554 in stock
Investing News at Macroaxis
over three weeks ago at www.macroaxis.com         
Disposition of 1924 shares by Christine Ring of Nurix Therapeutics subject to Rule 16b-3
Macroaxis News
over a month ago at finance.yahoo.com         
Nurix Therapeutics Announces Presentations atthe 7th Annual TPD Induced Proximity Summit
Yahoo News
over a month ago at www.macroaxis.com         
Acquisition by Kunkel Lori Anne of 25000 shares of Nurix Therapeutics at 16.19 subject to Rule 16b-3
Macroaxis News
over a month ago at thelincolnianonline.com         
Nurix Therapeutics Given New 26.00 Price Target at Royal Bank of Canada
news
over a year ago at news.google.com         
Global markets live Adobe, Eli Lilly, Nasdaq, Intel, UBS... - Marketscreener.com
Google News at Macroaxis
over a year ago at thelincolnianonline.com         
Boxer Capital LLC Boosts Stock Position in Prometheus Biosciences, Inc.
news
over a year ago at www.macroaxis.com         
Exercise or conversion by Mark McKenna of 122528 shares of Prometheus Biosciences subject to Rule 16...
Macroaxis News
over a year ago at news.google.com         
PROMETHEUS BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana Kahn Swick Foti, L...
Google News at Macroaxis
over a year ago at simplywall.st         
We Think Prometheus Biosciences Can Afford To Drive Business Growth
Simply Wall St News at Macroaxis
over a year ago at zacks.com         
Prometheus Biosciences, Inc. is a Great Momentum Stock Should You Buy?
zacks News
over a year ago at zacks.com         
Prometheus Biosciences, Inc. Reports Q1 Loss, Tops Revenue Estimates
zacks News
over a year ago at news.google.com         
Ieq Capital LLC Sells off 35.3 percent of Holding in Prometheus ... - Best Stocks
Google News at Macroaxis
over a year ago at news.google.com         
Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of Directors - Marketscre...
Google News at Macroaxis
over a year ago at fool.com         
Why Madrigal Pharmaceuticals Stock Gained 20 percent This Week
fool News
over six months ago at www.macroaxis.com         
Disposition of 8500 shares by Jonas Jeffrey M of Karuna Therapeutics at 128.01 subject to Rule 16b-3
Macroaxis News
over six months ago at bizjournals.com         
PureTechs newest biotech spinout represents a shift from the past
bizjournals News
over six months ago at news.google.com         
Disposition of 17350 shares by Stephen Brannan of Karuna Therapeutics at 187.26 subject to Rule 16b-...
Google News at Macroaxis
over six months ago at simplywall.st         
When Will Karuna Therapeutics, Inc. Turn A Profit?
Simply Wall St News at Macroaxis
over six months ago at news.google.com         
Karuna Therapeutics, Inc. Receives Consensus Recommendation of Hold from Analysts - Defense World
Google News at Macroaxis
over six months ago at finance.yahoo.com         
Bronte Amalthea Fund Incurred Loss in Karuna Therapeutics Short Position
Yahoo News
over six months ago at www.macroaxis.com         
Acquisition by Steven Paul of 47378 shares of Karuna Therapeutics at 315.18 subject to Rule 16b-3
Macroaxis News
over six months ago at seekingalpha.com         
Karuna Therapeutics stock drops on no apparent news amid deal with Bristol-Myers Squibb
seekingalpha News
over six months ago at thelincolnianonline.com         
Algert Global LLC Has 3.12 Million Stock Holdings in Karuna Therapeutics, Inc.
news
over six months ago at zacks.com         
Acquisition by Steven Paul of 27510 shares of Karuna Therapeutics at 7.27 subject to Rule 16b-3
zacks News
few days ago at news.google.com         
Brokers Set Expectations for Sutro Biopharma FY2024 Earnings - MarketBeat
Google News at Macroaxis
over a week ago at gurufocus.com         
Sutro Biopharma Inc Q3 2024 Earnings Revenue Misses Estimates at 8. ...
Gurufocus Stories at Macroaxis
over two weeks ago at gurufocus.com         
Vanguard Group Incs Strategic Acquisition in Sutro Biopharma Inc
Gurufocus Stories at Macroaxis
over a month ago at news.google.com         
Sutro Biopharma shareholders have endured a 80 percent loss from investing in the stock three years ...
Google News at Macroaxis
over a month ago at www.macroaxis.com         
Acquisition by Gerber Hans-peter of 175000 shares of Sutro Biopharma at 3.77 subject to Rule 16b-3
Macroaxis News
over a month ago at www.macroaxis.com         
Disposition of 31125 shares by Newell William J of Sutro Biopharma subject to Rule 16b-3
Macroaxis News
over two months ago at www.macroaxis.com         
Disposition of 13380 shares by Gerber Hans-peter of Sutro Biopharma at 3.95 subject to Rule 16b-3
Macroaxis News
over two months ago at finance.yahoo.com         
Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pip...
Yahoo News
over three months ago at globenewswire.com         
Sutro Biopharma Announces Initiation of REFRME-L1 Phase 2 Trial with Luvelta for Patients with Non-S...
Macroaxis News: globenewswire.com
over three months ago at simplywall.st         
Analysts Are Upgrading Sutro Biopharma, Inc. After Its Latest Results
Simply Wall St News at Macroaxis
over a year ago at news.google.com         
FDA approves Regenerons Eylea for retinopathy of prematurity - FiercePharma
Google News at Macroaxis
few days ago at investors.com         
Stocks Showing Rising Market Leadership Xencor Earns 83 RS Rating
Investors Business Daily at Macroaxis
few days ago at finance.yahoo.com         
Wall Street Analysts Believe Xencor Could Rally 53.53 percent Heres is How to Trade
Yahoo News
over a week ago at thelincolnianonline.com         
Xencor, Inc. VP John R. Desjarlais Sells 68,684 Shares of Stock
news
over a week ago at investing.com         
Xencors SWOT analysis biotech stock faces pivotal year ahead
Investing News at Macroaxis
over a week ago at investing.com         
Disposition of 3366 shares by Bassil Dahiyat of Xencor at 15.69 subject to Rule 16b-3
Investing News at Macroaxis
over a week ago at simplywall.st         
Xencor, Inc. Just Reported And Analysts Have Been Cutting Their Estimates
Simply Wall St News at Macroaxis
over two weeks ago at seekingalpha.com         
Xencor GAAP EPS of -0.71 beats by 0.30, revenue of 10.71M misses by 2.62M
seekingalpha News
over two weeks ago at thelincolnianonline.com         
Xencor Announces Earnings Results, Beats Estimates By 0.27 EPS
news
over two weeks ago at finance.yahoo.com         
Xencor Reports Q3 Loss, Tops Revenue Estimates
Yahoo News
over two weeks ago at businesswire.com         
Xencor Doses First Subject in Phase 12 Study of XmAb942 in Development for Patients with Inflammator...
businesswire News
a day ago at finance.yahoo.com         
Kura Oncology, Inc. Among the Most Promising Cancer Stocks According to Hedge Funds
Yahoo News
3 days ago at investing.com         
Google, Snowflake Stir Thursdays Market Cap Stock Movers
Investing News at Macroaxis
few days ago at gurufocus.com         
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and ...
Gurufocus Stories at Macroaxis
few days ago at medcitynews.com         
Disposition of 526 shares by Kathleen Ford of Kura Oncology at 16.0337 subject to Rule 16b-3
news
over a week ago at insidermonkey.com         
Kura Oncology, Inc. Q3 2024 Earnings Call Transcript
insidermonkey News
over two weeks ago at gurufocus.com         
Kura Oncology Inc Q3 2024 Earnings Call Highlights Strategic Advances Amid Rising Expenses
Gurufocus Stories at Macroaxis
over two weeks ago at seekingalpha.com         
Kura Oncology GAAP EPS of -0.63 in-line
seekingalpha News
over two weeks ago at globenewswire.com         
Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual M...
Macroaxis News: globenewswire.com
over three weeks ago at thelincolnianonline.com         
Kura Oncology, Inc. Short Interest Down 8.8 percent in October
news
over a month ago at finance.yahoo.com         
Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastroi...
Yahoo News
over a year ago at news.google.com         
The Clock Is Ticking For Seres Therapeutics Im Not Afraid ... - Seeking Alpha
Google News at Macroaxis
few days ago at news.google.com         
Allakos Reports Q3 2024 Results and Research Progress - TipRanks
Google News at Macroaxis
over a week ago at news.google.com         
FMR LLCs Strategic Acquisition of Allakos Inc Shares - GuruFocus.com
Google News at Macroaxis
over a month ago at simplywall.st         
Allakos Insiders Miss 24 percent Gain After Offloading Stock
Simply Wall St News at Macroaxis
over a month ago at thelincolnianonline.com         
JMP Securities Reaffirms Market Outperform Rating for Allakos
news
over two months ago at news.google.com         
Allakos stock plunges to 52-week low of 0.56 amid market challenges - Investing.com
Google News at Macroaxis
over two months ago at www.macroaxis.com         
Disposition of 13665 shares by Radford Harlan Baird of Allakos at 0.65 subject to Rule 16b-3
Macroaxis News
over three months ago at news.google.com         
Vanguard Group Inc. Raises Stock Holdings in Allakos Inc. - Defense World
Google News at Macroaxis
over three months ago at news.google.com         
Allakos stock plunges to 52-week low of 0.67 amid steep annual decline - Investing.com
Google News at Macroaxis
over three months ago at finance.yahoo.com         
Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
Yahoo News
over three months ago at finance.yahoo.com         
Can Allakos Afford To Invest In Growth?
Yahoo News
a day ago at www.macroaxis.com         
Disposition of 2000 shares by Lizzul Paul F. of AnaptysBio at 40.0 subject to Rule 16b-3
Macroaxis News
over a week ago at finance.yahoo.com         
Broker Revenue Forecasts For AnaptysBio, Inc. Are Surging Higher
Yahoo News
over a week ago at www.macroaxis.com         
Acquisition by Eric Loumeau of 29150 shares of AnaptysBio subject to Rule 16b-3
Macroaxis News
over two weeks ago at zacks.com         
AnaptysBio Upgraded to Buy What Does It Mean for the Stock?
zacks News
over two weeks ago at simplywall.st         
AnaptysBio, Inc. May Have Run Too Fast Too Soon With Recent 33 percent Price Plummet
Simply Wall St News at Macroaxis
over two weeks ago at kalkinemedia.com         
Revenue Rises to 30M in AnaptysBio Inc. Q3 2024, EPS of -1.14 Exceeds Estimates
news
over two weeks ago at thelincolnianonline.com         
AnaptysBio Issues Earnings Results, Beats Estimates By 0.58 EPS
news
over two weeks ago at seekingalpha.com         
AnaptysBio GAAP EPS of -1.14 beats by 0.51, revenue of 30.02M beats by 21.85M
seekingalpha News
over three weeks ago at thelincolnianonline.com         
HC Wainwright Reaffirms Buy Rating for AnaptysBio
news
over three weeks ago at investing.com         
AMD, Eli Lilly slide Google, Visa rise among Wednesdays afternoon market cap stock movers
Investing News at Macroaxis
3 days ago at investing.com         
Barclays bullish on argenx stock after positive trial results
Investing News at Macroaxis
few days ago at investing.com         
argenx shares see price target boosted by Raymond James, Strong Buy rating upheld
Investing News at Macroaxis
over a week ago at gurufocus.com         
Paradigm Biocapital Advisors LP Acquires Significant Stake in Nuvalent Inc
Gurufocus Stories at Macroaxis
over a week ago at gurufocus.com         
Deep Track Capital, LPs Strategic Acquisition of Korro Bio Inc Shares
Gurufocus Stories at Macroaxis
over a week ago at gurufocus.com         
FMR LLC Bolsters Stake in Argenx SE
Gurufocus Stories at Macroaxis
over a week ago at benzinga.com         
This Bristol-Myers Squibb Analyst Turns Bullish Here Are Top 5 Upgrades For Tuesday
benzinga news
over two weeks ago at thelincolnianonline.com         
argenx Rating Increased to Sector Outperform at Scotiabank
news
over three weeks ago at insidermonkey.com         
argenx SE Q3 2024 Earnings Call Transcript
insidermonkey News
over three weeks ago at thelincolnianonline.com         
argenx SE Short Interest Update
news
over three weeks ago at seekingalpha.com         
Argenx SE Q3 2024 Earnings Preview
seekingalpha News
2 days ago at news.google.com         
Ascendis Pharmas SWOT analysis stock faces growth hurdles amid pipeline promise - Investing.com Indi...
Google News at Macroaxis
six days ago at simplywall.st         
Ascendis Pharma Third Quarter 2024 Earnings Misses Expectations
Simply Wall St News at Macroaxis
over a week ago at investing.com         
Oppenheimer cuts Ascendis Pharma stock target, outperform on Q3 report
Investing News at Macroaxis
over a week ago at investing.com         
TD Cowen cuts Ascendis Pharma target to 153, keeps buy rating
Investing News at Macroaxis
over a week ago at gurufocus.com         
T. Rowe Price Investment Management, Inc. Expands Holdings in Ascendis Pharma AS
Gurufocus Stories at Macroaxis
over a week ago at seekingalpha.com         
Ascendis Pharma GAAP EPS of -1.72, revenue of 57.83M
seekingalpha News
over a week ago at seekingalpha.com         
Ascendis Pharma Q3 2024 Earnings Preview
seekingalpha News
over two weeks ago at finance.yahoo.com         
Heres Why BioMarin Aristotle Large Cap Growth Strategy Divested From Pharmaceutical
Yahoo News
over two weeks ago at benzinga.com         
Novo Nordisk Q3 Preview Will 285 Million Weight Loss Bet Offset Bearish Charts?
benzinga news
over two weeks ago at medcitynews.com         
Novo Nordisk Commits 285M to Ascendis to Kick Off Alliance on Longer-Acting GLP-1 Drugs
news
over a year ago at news.google.com         
Taysha The FDA Just Stuck A Major Blow To Their Plans - Seeking Alpha
Google News at Macroaxis
3 days ago at investing.com         
Biohavens SWOT analysis stock poised for potential growth amid clinical trials
Investing News at Macroaxis
over a week ago at thelincolnianonline.com         
Biohavens Buy Rating Reaffirmed at HC Wainwright
news
over a week ago at investing.com         
Biohaven stock target cut by analyst on model updates
Investing News at Macroaxis
over a week ago at prnewswire.com         
Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments
prnewswire News
over a month ago at finance.yahoo.com         
Amyotrophic Lateral Sclerosis Treatment Market to hit USD 1.1 billion by 2032, says Global Market In...
Yahoo News
over a month ago at news.google.com         
BofA sustains Buy rating on Biohaven shares, sees SMA trial upside - Investing.com
Google News at Macroaxis
over a month ago at finance.yahoo.com         
Why Pfizer Stock Popped on Monday
Yahoo News
over a month ago at investing.com         
Biohaven CEO Vlad Coric acquires 999,970 in company stock
Investing News at Macroaxis
over a month ago at prnewswire.com         
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purcha...
prnewswire News
over a month ago at finance.yahoo.com         
Biohaven Announces Pricing of 250 Million Public Offering of Common Shares
Yahoo News
2 days ago at investing.com         
Blueprint Medicines director Coats sells 1.87 million in stock
Investing News at Macroaxis
few days ago at thelincolnianonline.com         
JMP Securities Reaffirms Market Outperform Rating for Blueprint Medicines
news
over a week ago at benzinga.com         
Blood Cancer-Focused Blueprint Medicines Could Be Attractive Target For Partnerships Analyst
benzinga news
over a week ago at www.macroaxis.com         
Disposition of 5000 shares by Albers Jeffrey W. of Blueprint Medicines at 102.0 subject to Rule 16b-...
Macroaxis News
over two weeks ago at investors.com         
Stocks Showing Improved Relative Strength Blueprint Medicines
Investors Business Daily at Macroaxis
over two weeks ago at finance.yahoo.com         
Analysts Have Made A Financial Statement On Blueprint Medicines Corporations Third-Quarter Report
Yahoo News
over three weeks ago at finance.yahoo.com         
Blueprint Medicines Third Quarter 2024 Earnings EPS Beats Expectations
Yahoo News
over three weeks ago at investing.com         
Earnings call Blueprint Medicines sees revenue soar with AYVAKIT sales
Investing News at Macroaxis
over three weeks ago at gurufocus.com         
Blueprint Medicines Corp Q3 2024 Earnings Call Highlights Record AYVAKIT Revenue and ...
Gurufocus Stories at Macroaxis
over three weeks ago at seekingalpha.com         
Blueprint Medicines beats Q3 top and bottom-line estimates
seekingalpha News
few days ago at globenewswire.com         
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific An...
Macroaxis News: globenewswire.com
few days ago at kalkinemedia.com         
Celldex Therapeutics Insider Makes US308k Share Purchase
news
over a week ago at gurufocus.com         
Polar Capital Holdings Plc Reduces Stake in Celldex Therapeutics Inc
Gurufocus Stories at Macroaxis
over a week ago at investing.com         
Allakoss SWOT analysis biotech firms stock faces hurdles in CSU market
Investing News at Macroaxis
over a week ago at www.macroaxis.com         
Acquisition by Marucci Anthony S of 11500 shares of Celldex Therapeutics at 26.82 subject to Rule 16...
Macroaxis News
over two weeks ago at simplywall.st         
Celldex Therapeutics Third Quarter 2024 Earnings Beats Expectations
Simply Wall St News at Macroaxis
over two weeks ago at investing.com         
Stifel maintains buy on THRD with 23 target on study outlook
Investing News at Macroaxis
over two weeks ago at finance.yahoo.com         
Celldex Q3 Earnings Snapshot
Yahoo News
over three weeks ago at zacks.com         
Intra-Cellular Therapies Reports Q3 Loss, Tops Revenue Estimates
zacks News
over three weeks ago at gurufocus.com         
Celldex Therapeutics Reports Positive Results in Chronic Inducible Urticaria Study
Gurufocus Stories at Macroaxis
over a week ago at gurufocus.com         
COMMODORE CAPITAL LPs Strategic Acquisition in Cogent Biosciences Inc
Gurufocus Stories at Macroaxis
over a week ago at thelincolnianonline.com         
Cogent Biosciences Earns Neutral Rating from Wedbush
news
over a week ago at seekingalpha.com         
Cogent Biosciences GAAP EPS of -0.64 misses by 0.08
seekingalpha News
over two weeks ago at finance.yahoo.com         
Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hema...
Yahoo News
over a month ago at thelincolnianonline.com         
Cogent Biosciences Stock Rating Reaffirmed by Needham Company LLC
news
over a month ago at finance.yahoo.com         
Analysts Rate Cogent Biosciences, Inc. as Moderate Buy with 15 Target
Yahoo News
over a month ago at thelincolnianonline.com         
Citigroup Increases Cogent Biosciences Price Target to 15.00
news
over two months ago at finance.yahoo.com         
Cogent Biosciences, Inc. This Small-Cap Healthcare Stock Is A Good Buy Right Now
Yahoo News
over three months ago at news.google.com         
Hennion Walsh Asset Management Inc. Invests 1.08 Million in Cogent Biosciences, Inc. - MarketBeat
Google News at Macroaxis
over three months ago at news.google.com         
Cogent Biosciences Trading 10.1 percent Higher - MarketBeat
Google News at Macroaxis
3 days ago at news.google.com         
Swiss National Bank Increases Holdings in Exact Sciences Co. - MarketBeat
Google News at Macroaxis
few days ago at zacks.com         
EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test
zacks News
over a week ago at gurufocus.com         
Acquisition by Kevin Conroy of 19500 shares of EXACT Sciences at 51.35 subject to Rule 16b-3
Gurufocus Stories at Macroaxis
over a week ago at investing.com         
Exact Sciences CEO Kevin Conroy buys 1 million in stock
Investing News at Macroaxis
over a week ago at simplywall.st         
Why Investors Shouldnt Be Surprised By Exact Sciences Corporations 27 percent Share Price Plunge
Simply Wall St News at Macroaxis
over two weeks ago at gurufocus.com         
Wellington Management Group LLP Reduces Stake in Exact Sciences Corp
Gurufocus Stories at Macroaxis
over two weeks ago at thelincolnianonline.com         
Exact Sciences Issues Earnings Results
news
over two weeks ago at finance.yahoo.com         
Exact Sciences Third Quarter 2024 Earnings Misses Expectations
Yahoo News
over two weeks ago at investing.com         
Exact Sciences stock target cut by Benchmark, retains Buy rating
Investing News at Macroaxis
over two weeks ago at gurufocus.com         
Exact Sciences Corp Q3 2024 Earnings Call Highlights Strong Revenue Growth Amid ...
Gurufocus Stories at Macroaxis
over a year ago at businesswire.com         
Verily Appoints Utpal Koppikar as Chief Financial Officer
businesswire News
few days ago at thelincolnianonline.com         
Drive Wealth Management LLC Buys Shares of 14,350 908 Devices Inc.
news
over a week ago at gurufocus.com         
Granahan Investment Management Reduces Stake in 908 Devices Inc
Gurufocus Stories at Macroaxis
over a week ago at simplywall.st         
908 Devices Third Quarter 2024 Earnings Misses Expectations
Simply Wall St News at Macroaxis
over a week ago at investing.com         
Leerink downgrades 908 Devices stock rating on market headwinds, slashes PT
Investing News at Macroaxis
over a week ago at zacks.com         
908 Devices Inc. Reports Q3 Loss, Lags Revenue Estimates
zacks News
over two weeks ago at scmp.com         
Priest stabbed during mass in Singapore, attacker arrested
news
over two weeks ago at zacks.com         
Globus Medical Beats Q3 Earnings and Revenue Estimates
zacks News
over a month ago at businesswire.com         
908 Devices to Report Third Quarter 2024 Financial Results on November 12, 2024
businesswire News
over a month ago at gurufocus.com         
Disposition of 7777 shares by Hrusovsky E Kevin of 908 Devices subject to Rule 16b-3
Gurufocus Stories at Macroaxis
over two months ago at aol.com         
Historic New Jersey church holds final mass Today is a very sad day
news
a day ago at thelincolnianonline.com         
Vertex Pharmaceuticals Incorporated Shares Purchased by Cerity Partners LLC
news
3 days ago at investing.com         
BofA flags Vertex Pharma stock at risk of double top breakdown
Investing News at Macroaxis
few days ago at thelincolnianonline.com         
EULAV Asset Management Sells 4,500 Shares of Vertex Pharmaceuticals Incorporated
news
few days ago at investing.com         
KeyBanc maintains 12 target on Recursion Pharmaceuticals post-acquisition
Investing News at Macroaxis
few days ago at finance.yahoo.com         
Vertex Pharmaceuticals Incorporated is Attracting Investor Attention Here is What You Should Know
Yahoo News
few days ago at watcher.guru         
2 Hot Picks for Monday in the US Stock Market
news
six days ago at finance.yahoo.com         
Vertex Resource Group Third Quarter 2024 Earnings EPS CA0.02
Yahoo News
over a week ago at zdnet.com         
Want generative AI LLMs integrated with your business data You need RAG
news
over a week ago at finance.yahoo.com         
Vertex Resource Group Ltd. Reports Record Third Quarter 2024 Results
Yahoo News
over a week ago at thelincolnianonline.com         
Vertex Pharmaceuticals Incorporated Shares Bought by Pinnacle Financial Partners Inc
news
a day ago at thelincolnianonline.com         
Benjamin L. Palleiko Sells 14,400 Shares of KalVista Pharmaceuticals, Inc. Stock
news
few days ago at www.macroaxis.com         
Disposition of 8077 shares by Audhya Paul K. of Kalvista Pharmaceuticals at 9.2566 subject to Rule 1...
Macroaxis News
over a week ago at gurufocus.com         
Vestal Point Capital, LP Increases Stake in KalVista Pharmaceuticals Inc
Gurufocus Stories at Macroaxis
over two weeks ago at finance.yahoo.com         
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635
Yahoo News
over two weeks ago at businesswire.com         
KalVista Pharmaceuticals Announces Pricing of a 55 Million Underwritten Offering of Common Stock and...
businesswire News
over two weeks ago at seekingalpha.com         
KalVista prices 55M stock offering
seekingalpha News
over a month ago at finance.yahoo.com         
KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American Colle...
Yahoo News
over a month ago at businesswire.com         
KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American Colle...
businesswire News
over a month ago at finance.yahoo.com         
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635
Yahoo News
over a month ago at gurufocus.com         
TANG CAPITAL MANAGEMENT LLC Acquires New Stake in ITeos Therapeutics Inc
Gurufocus Stories at Macroaxis
3 days ago at gurufocus.com         
uniQure Announces Dosing of First Patient in GenTLE Phase IIIa Clinical Trial of AMT-260 for ...
Gurufocus Stories at Macroaxis
over a week ago at news.google.com         
uniQure NV Enterprise Value -65.19 Mil - GuruFocus.com
Google News at Macroaxis
over two weeks ago at thelincolnianonline.com         
uniQure Releases Quarterly Earnings Results, Beats Expectations By 0.21 EPS
news
over two weeks ago at finance.yahoo.com         
uniQure Third Quarter 2024 Earnings EPS Beats Expectations, Revenues Lag
Yahoo News
over two weeks ago at gurufocus.com         
uniQure NV Q3 2024 Earnings EPS Loss of 0.91 Beats Estimates, Revenue of 2. ...
Gurufocus Stories at Macroaxis
over three weeks ago at zacks.com         
Amicus Therapeutics Reports Next Week Wall Street Expects Earnings Growth
zacks News
over a month ago at gurufocus.com         
State Street Corps Strategic Reduction in uniQure NV Holdings
Gurufocus Stories at Macroaxis
over a month ago at finance.yahoo.com         
uniQure Announces Dosing of First Patient in Phase III Clinical Trial of AMT-162 for the Treatment o...
Yahoo News
over a month ago at simplywall.st         
uniQure NASDAQQURE shareholders incur further losses as stock declines 10 percent this week, taking ...
Simply Wall St News at Macroaxis
over two months ago at globenewswire.com         
uniQure Announces Orphan Drug Designation Granted toAMT-191 for the Treatment of Fabry Disease
Macroaxis News: globenewswire.com
3 days ago at seekingalpha.com         
Sage raised to sector perform by RBC in wake of drug failure
seekingalpha News
few days ago at businesswire.com         
Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor in the T...
businesswire News
few days ago at bizjournals.com         
Third trial failure is end-of-the-road for Sages neurological drug
bizjournals News
over a week ago at accesswire.com         
SOHM, Inc. Announces Allowances Of Japanese Patent Claims Received from Japans Patent Office Protect...
news
over two weeks ago at finance.yahoo.com         
Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer Head of Quality
Yahoo News
over three weeks ago at thelincolnianonline.com         
Sage Therapeutics Price Target Cut to 8.00 by Analysts at Oppenheimer
news
over three weeks ago at bizjournals.com         
Cambridge biotechs layoffs will cut dozens of Mass. employees
bizjournals News
over three weeks ago at globenewswire.com         
Sage and Artis Trade Join Forces to Accelerate Document Automation and Drive Efficiency in Secured F...
Macroaxis News: globenewswire.com
over three weeks ago at thelincolnianonline.com         
Sage Therapeutics Given Hold Rating at Needham Company LLC
news
over three weeks ago at accesswire.com         
Class Action Filed Against Sage Therapeutics, Inc. Seeking Recovery for Investors - Contact Levi Kor...
news
Far too much social signal, news, headlines, and media speculation about Eventide Healthcare that are available to investors today. That information is available publicly through Eventide media outlets and privately through word of mouth or via Eventide internal channels. However, regardless of the origin, that massive amount of Eventide data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Eventide Healthcare news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Eventide Healthcare relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Eventide Healthcare's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Eventide Healthcare alpha.

Other Information on Investing in Eventide Mutual Fund

Eventide Healthcare financial ratios help investors to determine whether Eventide Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Eventide with respect to the benefits of owning Eventide Healthcare security.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Bonds Directory
Find actively traded corporate debentures issued by US companies
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges